Method for revaccination in adults against diphtheria and tetanus in far north

FIELD: medicine.

SUBSTANCE: the present innovation deals with technique of revaccination in adults against diphtheria and tetanus under conditions of Far North. For this purpose one should form a group of people vaccinated more than 10 years ago to vaccinate them in February. The method leads to increased efficiency of vaccination due to decreased duration of vaccination period.

EFFECT: higher efficiency of revaccination.

7 ex

 

The invention relates to medicine and can be used for vaccination with diphtheria and tetanus among the adult population of the Far North.

There is a method of vaccination DT-m toxoid adults through 10 years after the last vaccination against diphtheria and tetanus [Ministry of health of the Russian Federation. New immunization schedule Russia. Order No. 229. - M, 27.06.2001].

The known method does not take into account changes in the immune system after an abrupt change in climatic conditions "polar night and polar day" for short seasons of the Northern spring, summer and autumn and long cold winters in the Far North. This reduces the effectiveness of preventive vaccination and increases the likelihood of diphtheria and tetanus. In addition, vaccination by a known method in different seasons during the year in the Far North requires significant material and labor costs for the work of medical teams and helicopter transport.

The objective is to increase the effectiveness of vaccination of the adult population of the Far North against diphtheria and tetanus and reduced material and labor costs.

The method revaccination of adults against diphtheria and tetanus in the Far North is vaccination DT-m Anat is by xing every 10 years after the last vaccination, thus, according to the invention, form a group of people vaccinated more than 10 years ago, and Vaccinium them from February to July.

In humans, living in the Far North, formed the most intense post-vaccination immunity in the period from February to July. This increases the effectiveness of vaccination. In addition, the reduced period of vaccination and costs.

The method is as follows. In the Far North are selected adults vaccinated against diphtheria and tetanus 10 or more years ago, in a separate group, and each of them administered the vaccine DT-m toxoid in the period from February to July.

Example 1. M (age 30 years). Previous vaccination against diphtheria and tetanus were 12 years ago. Included in the group of persons eligible for vaccination against diphtheria and tetanus. Grafted DT-m toxoid in January. 1 year after vaccination diphtheria and tetanus antivenoms are respectively identified in the credits: <1:10 and 1:10 - seronegative.

Example 2. A. (age 49 years). Previous vaccination against diphtheria and tetanus conducted 25 years ago. Included in the group of persons eligible for vaccination against diphtheria and tetanus. Grafted DT-m toxoid in the month of February. 1 year after vaccination diphtheria and tetanus antivenoms are respectively identified in the captions: 1:160 and 1:320.

P the emer 3. N. (age 42 years). Previous vaccination against diphtheria and tetanus spent 19 years ago. Included in the group of persons eligible for vaccination against diphtheria and tetanus. Grafted DT-m toxoid in the month of April. 1 year after vaccination diphtheria and tetanus antivenoms are respectively identified in the captions: 1:320 and 1:640.

Example 4. O. (age 34 years). Previous vaccination against diphtheria and tetanus conducted 18 years ago. Included in the group of persons eligible for vaccination against diphtheria and tetanus. Grafted DT-m toxoid in the month of July. 1 year after vaccination diphtheria and tetanus antivenoms are respectively identified in the captions: 1:640 1:1280.

Example 5. I. (age 31 years). Previous vaccination against diphtheria and tetanus conducted 15 years ago. Included in the group of persons eligible for vaccination against diphtheria and tetanus. Grafted DT-m toxoid in the month of August. 1 year after vaccination diphtheria and tetanus antivenoms are respectively identified in the captions: 1:10 <1:10 - seronegative.

Example 6. A. (age 27 years). Previous vaccination against diphtheria and tetanus conducted 10 years ago. Included in the group of persons eligible for vaccination against diphtheria and tetanus. Grafted DT-m toxoid in the month of October. 1 year after vaccination diphtheria, etc is tibetanmachine antivenoms are respectively identified in the captions: 1:10 < 1:10 - seronegative.

Example 7. Century (age 52 years). Previous vaccination against diphtheria and tetanus spent 27 years ago. Included in the group of persons eligible for vaccination against diphtheria and tetanus. Grafted DT-m toxoid in the month of December. 1 year after vaccination diphtheria and tetanus antivenoms are respectively identified in the credits: <1:10 <1:10 - seronegative.

Only in the Far North grafted DT-m toxoid 648 people. All observed grafted through 10-28 years after the last vaccination against diphtheria and tetanus.

The use of the proposed method has the following advantages:

1. Improving the effectiveness of vaccination of people living in the Far North and reducing the risk of diphtheria and tetanus.

2. Reducing material and labor costs for the maintenance of medical teams and vehicles (helicopters) by reducing the period of vaccination.

The way revaccination of adults against diphtheria and tetanus in the far North, which consists in vaccination DT-m toxoid, characterized in that forming a group of people vaccinated more than 10 years ago, and Vaccinium them in February.



 

Same patents:

FIELD: medicine, obstetrics.

SUBSTANCE: one should conduct antibacterial therapy 3 mo before planned pregnancy consisting of preparations of tetracyclinic group or macrolides in combination with nystatin and metronidasol to continue it since the first day of menstrual cycle and, also, it is necessary to perform correction of vaginal biocenosis, and about 3-4 wk after therapy carried out for 2 next mo before planned pregnancy starting, also, since the first day of menstrual cycle - metabolic therapy; At the onset of pregnancy one should conduct courses for preventing placental deficiency dealing with introduction of preparations that improve uterine-placental circulation, and preparations that improve rheological properties of blood and vitamin-metabolic therapy or the same preparations, and additionally - introduction of macrolides ad viferon rectally in case of activation of chlamydial infection. The present innovation enables to sanitize uterine cavity, improve uterine-placental circulation, restoration of placental tissue structure that, in its turn favors the birth of healthy generation.

EFFECT: higher efficiency of prophylaxis.

1 cl, 9 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: medicinal formulation possessing the bacteristatic effect consists of a core comprising the following components, wt.-%: clarithromycin, 40.0-80.0; polyvinylpyrrolidone, 3.0-10.0; sodium lauryl sulfate, 2.0-5.0; sodium croscarmelose, 4.0-10.0; aerosil, 0.5-2.0; magnesium stearate, 0.5-2.0, and microcrystalline cellulose, 10.0-31.0. Also, the medicinal formulation consists of envelope comprising the following components, wt.-%: hydroxypropylmethylcellulose, 30.0-70.0; polyethylene glycol, 12.0-22.0; titanium dioxide, 11.0-20.0, hydroxypropylcellulose, 2.0-10.0, dye yellow quinoline, 1.0-4.0, and vanillin, 1.0-4.0. Also, invention describes a method for preparing the medicinal formulation by wet granulation followed by tableting and applying the envelope from an aqueous suspension. Prepared tablets show the necessary mechanical strength, insignificant scattering index by mass (± 3.5%) and dissolving 88-91% for 30 min.

EFFECT: improved and valuable properties of medicinal formulation.

3 cl, 2 tbl

FIELD: medicine, gynecology, surgery.

SUBSTANCE: one should introduce 3.5%-chitosan ascorbate gel into fistulous channel that contains metronidasol at the dosage of 2 mg/ml, at the volume up to 20 ml once/2 d till complete fistula's closing. The present innovation enables to activate reparative processes and fistulous epithelization that favors for closing fistulous channel in earlier terms.

EFFECT: higher efficiency of therapy conducted.

2 ex

FIELD: medicine, surgery.

SUBSTANCE: one should apply a polycompositional film onto donor's wounds after autodermoplasty performed. This film contains the following components in weight proportions: chitosan 78.3-89.4; polyvinyl alcohol 9.8-19.8; antibiotic of aminoglycoside group 0.5-2.0; anesthetic 0.1-0.2. It is perforated at tension coefficient being 1:4. The innovation enables to decrease wound's traumatization, improves prophylaxis of suppuration and increases cosmetic effect even at a single application of the film suggested.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with application of pleuromutilin derivatives, that is valnemulin and thiamulin, for transdermal treatment of bacterial diseases, in particular those induced by Dichelobacter nodosus, Fusobacterium necrophorum, Bacteriodes nodosus and Bacteriodes melamnogenicus, for manufacturing medicinal preparation or as an active ingredient of medicinal preparation of the same indication and corresponding method for transdermal treatment of diseases, for example foot rot. It has been detected the capacity of antibiotics to penetrate skin and enter either plasma or blood at concentrations being efficient against systemic bacterial infections, so, medicinal preparation could be designed in the form of ointment, cream, solution, shampoo, powder and spray.

EFFECT: higher efficiency of application.

9 cl, 1 tbl

FIELD: biotechnology, immunology.

SUBSTANCE: invention proposes preparation that comprises the immunoelectrophoretically pure secretory immunoglobulin A isolated from whey milk and/or colostrum of immunized ungulate animals and pharmaceutically acceptable vehicles. The base preparation (substance) comprises 6-12% of secretory immunoglobulin A at pH 4-8, an anti-complementary activity at least 10 mg of protein, not activating 2 CH50, protects in >70% against corresponding infections (in infection macroorganism in doses ≥10 ID50), shows areactogenic property in intravenous administration, can comprise stabilizing additives in the total concentration 4%, not above. The preparation possesses high purity, low anti-complementary activity, stable in storage, useful for oral, parenteral and topical using and possesses therapeutic activity with respect to microorganisms and viruses against which humans and animals immunization have been carried out. Invention can be used in treatment and prophylaxis of immunodeficiency states, bacterial and viral infections in humans and animals.

EFFECT: valuable medicinal and veterinary properties of preparation.

9 cl, 1 tbl, 10 ex

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention relates to novel heterocyclic compounds comprising 2-aminopyridin-3-sulfonic fragment of the general formula (1) or their pharmaceutically acceptable salts, N-oxides or hydrates possessing properties of antagonists of glutamate-induced calcium ions transport, in particular, neuroprotective effect. Also, invention relates to the focused library for the search of biologically active leader-compounds comprising at least one heterocyclic compound of the general formula (1) and to pharmaceutical composition if form of tablets, capsules or injections placed into pharmaceutically acceptable package containing compounds of invention as an active substance. In compound of the general formula (1) R1 represents hydrogen atom; R2 represents chlorine atom, optionally substituted hydroxyl group, optionally substituted amino-group, optionally substituted azaheterocyclyl; or R1 and R2 in common with nitrogen and sulfur atoms to which they are bound form optionally substituted and optionally condensed with other cycles 1,1-dioxo-4H-pyrido[2,3-e][1,2,4]thiadiazine or optionally substituted and optionally condensed with other cycles 5,5-dioxo-5,6,7,9-tetrahydro-5-thia-1,6,9-triazabenzocyclohepten-8-one. Also, invention discloses methods for preparing different compounds of the general formula (1).

EFFECT: improved preparing methods, valuable medicinal properties of compounds.

10 cl, 4 sch, 4 tbl, 9 ex

FIELD: organic chemistry, biochemistry, pharmacy.

SUBSTANCE: invention relates to new heterocyclylsulfonyl alkylcarboxylic acids and their derivatives of the general formula (1): or their pharmaceutically acceptable salts, N-oxides or hydrates possessing the inhibitory effect on kinase activity and to the focused library for search of active leader-compounds comprising at least abovementioned compound. In the general formula 91) W represents optionally substituted heterocyclic radical, among them: pyrrole-3-yl, thiophene-2-yl, isooxazole-4-yl, pyrazole-4-yl, imidazole-4-yl, pyridine-3-yl, 1H-2,4-dioxopyrimidine-5-yl, 2,3-dihydro-1H-indole-5-yl, 2,3-dihydro-1H-indole-7-yl, 1,3-dihydro-2-oxoindole-5-yl, 2,3-dioxo-1H-indole-5-yl, 2-oxo-3H-benzoxazole-6-yl, benzothiazole-6-yl, 1H-benzimidazole-5-yl, benzo[1,2,5]oxadiazole-4-yl, benzo[1,2,5]thiadiazole-4-yl, 1,2,3,4-tetrahydroquinoline-6-yl, 3,4-dihydro-2-oxo-1H-quinoline-6-yl, quinoline-8-yl, 1,4-dihydro-2,3-dioxoquinoxaline-6-yl, 3-oxo-4H-benzo[1,4]oxazine-7-yl, 3-oxo-4H-benzo[1,4]thiazine-7-yl, 2,4-dioxo-1H-quinazoline-6-yl, 2,4-dioxo-1,5-dihydrobenzo[b][1,4]diazepine-7-yl or 2,5-dioxo-3,4-dihydrobenzo[b][1,4]diazepine-7-yl; Y represents optionally substituted methylene group; R1 represents chlorine atom, optionally substituted hydroxyl group, optionally substituted amino-group, optionally substituted azaheterocyclyl; n = 1, 2 or 3; or Yn represents carbon atom of optionally substituted (C3-C7)-cycloalkyl or optionally substituted (C4-C7)-heterocyclyl. Also, invention relates to a pharmaceutical composition in form of tablets, capsules or injections placed into pharmaceutically acceptable package.

EFFECT: valuable properties of compounds.

5 cl, 3 sch, 5 tbl, 6 ex

FIELD: organic chemistry, chemical technology, antibiotics.

SUBSTANCE: derivative of 9-deoxo-9a-aza-9a-homoerythromycin A of the formula (3) wherein R4 represents hydroxyl protecting group is prepared by protection of 2'-hydroxy-group of compound of the formula (5) to form compound of the formula (4)

and by oxidation of C-4''-hydroxy-group of compound of the formula (4) that is carried out by addition of dimethylsulfoxide to solution containing compound of the formula (4) and a solvent followed by cooling the mixture up to about -70°C, activation of dimethylsulfoxide in situ and defoaming the reaction mixture. Compound of the formula (4) is converted to the oxidation stage directly without its isolation. Also, invention proposes additive salt of trifluoroacetic acid of compound of the formula (3) and a method for its preparing by treatment of compound of the formula (3) with trifluoroacetic acid. Invention provides increasing yield and improving purity of the end product.

EFFECT: improved preparing method.

11 cl, 6 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with infecting macrophages and cells of macrophagous cell lines with pathogenic microorganisms, their treatment with medicinal remedies followed by gamma-irradiation, immunization of disease-resistant and disease-sensitive animal lines and infecting vaccinated animals with alive pathogenic microorganisms that leads to improved immunity to pathogenic microorganisms.

EFFECT: higher efficiency.

4 cl, 1 dwg, 3 ex

FIELD: medicine, vaccines.

SUBSTANCE: invention relates to a method for producing the combined vaccine comprising antigens of diphtheria, tetanus, whooping cough and hepatitis B. method involves stages of independent adsorption of each protective antigen on aluminum hydroxide used as a gel-adsorbent to different antigens: diphtheria, tetanus, whooping cough and hepatitis B followed by mixing adsorbed antigens. Advantage of invention involves the development of a method providing the improved evaluation and prophylaxis of adverse effect.

EFFECT: improved producing method.

11 cl, 3 dwg, 1 tbl, 10 ex

The invention relates to medicine, namely to methods for treating chronic bacterial infections

The invention relates to immunobiological industry and relates to vaccines against infections on the basis of a vaginal suppository
The invention relates to the field of veterinary Mycology

The invention relates to medicine, in particular to surgery, and can be used for the prevention of inflammatory complications accidental traumatic and surgical wounds
The invention relates to the field of veterinary medicine and biotechnology

FIELD: medicine, vaccines.

SUBSTANCE: invention relates to a method for producing the combined vaccine comprising antigens of diphtheria, tetanus, whooping cough and hepatitis B. method involves stages of independent adsorption of each protective antigen on aluminum hydroxide used as a gel-adsorbent to different antigens: diphtheria, tetanus, whooping cough and hepatitis B followed by mixing adsorbed antigens. Advantage of invention involves the development of a method providing the improved evaluation and prophylaxis of adverse effect.

EFFECT: improved producing method.

11 cl, 3 dwg, 1 tbl, 10 ex

Up!